MyFinsight
Home
Blog
About
Net income
$24,711K
(1.99%↑ Y/Y)
Accrued royalties
$21,622K
(61.31%↑ Y/Y)
Depreciation and
amortization
$19,640K
(-57.46%↓ Y/Y)
Accrued expenses,
accrued compensation,...
$12,835K
(345.98%↑ Y/Y)
Stock-based compensation
$11,406K
(-38.25%↓ Y/Y)
Accrued government
rebates
$2,975K
(-78.98%↓ Y/Y)
Returned goods reserve
$960K
(-89.80%↓ Y/Y)
Non-cash operating lease
expense
$456K
(-46.10%↓ Y/Y)
Non-cash interest
$357K
(-46.32%↓ Y/Y)
Inventories
-$305K
(-119.90%↓ Y/Y)
Net cash and cash
equivalents provided by...
$56,669K
(-48.86%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$67K
(-87.68%↓ Y/Y)
Canceled cashflow
$38,598K
Net change in cash,
cash equivalents,...
$49,035K
(-32.77%↓ Y/Y)
Canceled cashflow
$7,701K
Accounts receivable, net
$19,077K
(414.34%↑ Y/Y)
Prepaid expenses and
other assets
$10,334K
(275.45%↑ Y/Y)
Deferred taxes
-$4,938K
(28.63%↑ Y/Y)
Income taxes
-$1,770K
(48.77%↑ Y/Y)
Accounts payable
-$1,116K
(-112.94%↓ Y/Y)
Unrealized (gain) loss on
investment in equity...
$741K
(225.81%↑ Y/Y)
Contingent consideration
fair value...
-$622K
(94.25%↑ Y/Y)
Proceeds from stock
option exercises and...
$308K
(-91.84%↓ Y/Y)
Net cash and cash
equivalents used in...
-$4,647K
(60.12%↑ Y/Y)
Net cash and cash
equivalents used in...
-$3,054K
(88.59%↑ Y/Y)
Canceled cashflow
$308K
Principal payments on
borrowings
$4,062K
(0.00%↑ Y/Y)
Treasury stock purchases
for restricted...
$813K
(-92.30%↓ Y/Y)
Acquisition of property and
equipment, net
$3,054K
(-52.93%↓ Y/Y)
Payment of novitium
contingent consideration
$80K
Back
Back
Cash Flow
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)
source: myfinsight.com